rcsi collaborating with industry to improve human … rcsi... · 2018-08-01 · rcsi collaborating...

RCSI COLLABORATING WITH INDUSTRY TO IMPROVE HUMAN HEALTH

Leading the worldto better health

Pictured (L-R) are Professor Tracy Robson, Head of Molecular & Cellular Therapeutics, RCSI; Professor Tim Harrison, Vice President Discovery Chemistry, Almac Discovery and Dr Graham Cotton, Senior R&D Group Leader, Almac Discovery.

1RCSI Collaborating with Industry to Improve Human Health

Table of Contents

Welcome from RCSI 2

RCSI at a glance 3

RCSI’s Research Focus Areas 4

Industry Engagement at RCSI 5

Why Partner with RCSI? 6

Funding your Company’s Research Project at RCSI 7

Our Industry Engagement Process 8

Case Studies 9 1: Integra Lifesciences 10 2: Fleming Medical 12 3: Almac 14 4: Athena Diagnostics 16 5: Wellman International 18 6: Inflection Biosciences 20 7: Aerogen 22

RCSI: Playing a leading role in National Research Centres of scale 24

IP Commercialisation 26

Start-up Company Formation 27

RCSI’s Clinical Research Centre 28

Publication Impact 29

Contact us 30

Location 31

2 RCSI Collaborating with Industry to Improve Human Health

Since its establishment in late 2014, the Innovation Team in RCSI’s Office of Research and Innovation (ORI) has forged a reputation for professionalism, flexibility and expediency in our approach to research commercialisation and engagement with industry.

In recognition of the importance of industry engagement, we have a dedicated Head of Industry Partnerships, Dr Seamus Browne, who is a single point of contact for all industry partnerships and consultancy engagements.

As outlined in the coming pages, there are many ways that industry can work with us. Through our experience and knowledge, we can expedite the identification of appropriate funding supports for industry-RCSI collaborations leading to efficient project set-up, implementation and knowledge transfer. We encourage industry partners aligned with RCSI’s research strengths in biomaterials and regenerative medicine, cancer, neurological and psychiatric disorders, vascular biology, population health and health services, respiratory medicine and surgical science and practice to contact us and see how engaging with our researchers and clinical partners can add value to your business.

Dr Aoife Gallagher, Head of Innovation

At RCSI we have a dynamic research culture with global reach and celebrate a historic legacy of over 230 years of clinical innovation as well as unrivalled expertise in surgical training and practise. We have built a sustainable environment for growth and innovation as evidenced by our recent investments in the RCSI Strategic Academic Recruitment Programme (StAR) and in 26 York Street, Europe’s most advanced clinical healthcare simulation facility. We are proud to be ranked among the top 250 universities worldwide in the Times Higher Education World University Rankings (2018) and are driven by our ambition to continue delivering highly impactful research that improves human health, as illustrated by our recent publications in The New England Journal of Medicine, The Lancet, Nature and Science, that improve human health.

Partnering with industry and the commercialisation of our research outputs through spinout companies and licensing is an integral part of our research strategy. Such partnerships and activities are vitally important to delivering on our mission to improve human health and patient outcomes on a global scale.

We look forward to discussing how we can collaborate with your organisation.

Prof. Cathal J. Kelly Chief Executive

Welcome from RCSI


RCSI at a glance

3

No.1 Highest research paper impact (citation rate) in Ireland

>200%Increase in inventions identified by RCSI researchers since 2016

1784FOUNDED IN

of surgical training in Ireland

Sole provider

Times Higher Education World University Rankings 2017

TOP

2%Founding partner in

4 SFI funded Research Centres

€80mInvested in Europe’s most advanced clinical healthcare simulation facility at 26 York Street

400%increase in research agreements with Industry since 2014

€11mInvested in extending the RCSI Education and Research building at Beaumont Hospital

Hospitals in RCSI Hospital Group

7 ACADEMIC PARTNER TO

60 Students from 60 countries

4 Overseas campuses in Malaysia (2), Bahrain and Dubai

INDUSTRY PARTNERSHIPS

No.1 for H2020 Highest overall success rate for Horizon 2020 grants awarded to Irish Institutions

INTERNATIONAL OUTLOOK


RCSI has significantly enhanced its research capability, competitiveness and impact. An indicator of the growing impact of RCSI researchers on the international health sciences research landscape can be seen in how frequently our research is cited by other researchers. RCSI’s field-weighted citation impact is the highest in Ireland and twice the world average.

Our research programmes drive scientific breakthroughs, innovations and insights that allow us to understand and respond to changing healthcare needs and contribute to the development of new therapeutics, diagnostics, devices and healthcare system change that will enhance patient treatment and care in the future.

With a focus on clinical and patient-centred research, we have succeeded in leading impactful research that addresses key Irish and international health challenges. Supported by significant continuous investment in research infrastructure and systems, we focus relentlessly on quality and impact.

RCSI research - improving human health

Cancer

Neurological and Psychiatric Disorders

Biomaterials & Regenerative Medicine

Surgical Science and Practice

Vascular Biology

Population Health and Health Services

RCSI RESEARCH CENTRES OF EXCELLENCE


At RCSI, we believe meaningful engagement, collaboration and partnership with industry is an essential component to achieving our research mission. We are deeply interested in working with industry, both multinational corporations (MNCs) and small and medium-sized enterprises (SMEs) in the areas of cancer, biomaterials and regenerative medicine, neurodegenerative and psychiatric disorders, surgical science and practice, population health and health sciences, respiratory medicine and vascular biology through the following mechanisms:

As a higher education institute with an exclusive focus on human health, RCSI can offer unique opportunities for industry that include:

• Access to well-defined translational research programmes, internationally recognised research teams, clinical expertise and networks and state-of-the-art biomedical and clinical research infrastructure.

• A professional industry relationship management team to ensure ease of, benefit from, and co-ordination of engagement with RCSI researchers.

• Access to RCSI’s expertise and knowledge of appropriate National and European funding programmes to co-fund your project.

• An efficient, agile approach to negotiation of contracts with industry due to our size and status.

• Access to an array of therapeutics, diagnostics and medical device technologies available for commercial exploitation.

Industry engagement at RCSI

Industry directed

• Research directed by company

• Company pays full cost of project

• Possible for company to own project results

Industry informed

• Research informed by industry but directed by academia

• No company funding required

• No company pre-emptive rights to project results

Industry collaborative

• Research directed collaboratively by industry and academia

• Company typically pays a proportion of project costs

• Option to licence project results


Collaborate for success with RCSIRCSI’s Office of Research and Innovation (ORI) facilitates engagements between industry and the RCSI research community.

RCSI provides your company with access to:

• World class research capability willing to focus on your challenges

• State of the art surgical simulation, medical training facilities and research infrastructure

• Significant leveraged research funding opportunities

• New intellectual property assets

• Clinical expertise and network of clinicians in the RCSI hospital group

• Clinical research infrastructure

• Bespoke training programmes for company staff

If you are interested in informing, collaborating or directing research at RCSI, please contact us to discuss how we can partner with your organisation to drive innovation and significantly enhance your competitive advantage.

Why partner with RCSI?

Pictured: RCSI’s new €80M, Medical Education Building, 26 York Street.


RCSI’s ORI has experienced staff that will help your company navigate the complicated National and International funding landscape to identify the most appropriate funding programme for your particular research need. Examples of such funding programmes are provided below:

Funding Mechanism Objective

100% Industry Funding Allows your company to work with RCSI to address a specific research question where expeditious project set-up is critical. Project value and duration is at your company‘s discretion.

EI Innovation Partnership Programme

Enables your company, provided it is located in Ireland, to access RCSI’s research expertise and infrastructure in a mutually-beneficial collaborative effort to improve your company’s products, processes or services.

SFI Research Centre Targeted Projects, Rolling Spoke Programme and Fixed Spoke Programme

Provides a mechanism for your company to engage in new collaborative research projects involving RCSI researchers and existing SFI research centres.

SFI Strategic Partnership Programme Supports standalone collaborative research initiatives of scale between your company and RCSI that can demonstrate strong potential for delivering economic and social impact.

SFI Industry Fellowship Programme Facilitates (a) embedding RCSI researchers in your company; or (b) your company embedding company personnel in RCSI.

Horizon 2020 Funding H2020 funding schemes are based on competitive calls and are open to research institutes and companies. A wide range of research and innovation topics are covered. RCSI can provide guidance to your company on the mechanisms and options available, as well as support for the application process.

IRC Employment-based Postgraduate Award

Provides support for an employee in your company to pursue a MSc or a PhD degree at RCSI.

IRC Postgraduate and Postdoctoral Enterprise Partnership Award

Develops partnerships between your company and RCSI research groups through co-supervised MSc, PhD and Postdoctoral projects.

RCSI Strategic Industry Partnership Seed Fund

Provides your company with a mechanism of seed funding engagement with RCSI researchers that are not met through other funding schemes and can demonstrate potential to grow into high value collaborative opportunities.

EI Innovation Voucher Programme Allows your company, provided it is located in Ireland, to engage with RCSI researchers to perform an initial exploration of a collaborative research opportunity or challenge.

Funding your company’s research project


Our industry engagement process

Listen to company need and identify competencies and

infrastructure to solve challenge

Agree projectfocus and the most appropriate project funding mechanism

Support the preparation and submission of

funding proposal

Ongoing project management and

reporting to ensure timely focused project delivery

Transfer project results to company

1 Listen

2 Agree

3 Support

4 Manage

5 Transfer


Case studiesRCSI has partnered with a wide range of companies to address a number of healthcare challenges resulting in improved diagnostics, therapeutics, devices, enhanced healthcare delivery, clinical practice and healthcare professional education. Models of engagement vary and are tailored to meet the company’s requirements as illustrated in the following case studies.

INFLECTION


Title: Regeneration of damaged peripheral nerves

Engagement Type: SFI Research Centre Fully-Funded Research Project

Industry Partner: Integra Lifesciences is a global leader in medical technology offering innovative solutions including regenerative technologies, speciality surgical solutions, orthopaedics and tissue repair technologies.

Challenge: Peripheral nerve injury is a major clinical problem known to affect more than five million people worldwide every year. It is estimated that five percent of multiple trauma patients have peripheral nerve injuries. Prompt surgical intervention is needed. If the injury size is larger than five millimetres, the primary treatment option available in most cases is by autograft. This involves removal of nerve tissue from another part of the patient’s body and transplantation to the site of injury. Unfortunately, autografts are hampered by a number of issues including the limited availability of donor tissue and poor functional recovery for patients.

RCSI value-added World class biomaterials research expertise in restoring the structural and functional properties of damaged or degenerated tissue based in RCSI’s Tissue Engineering Research Group.

INTEGRA LIFESCIENCES

“RCSI’s researchers at the SFI research centre AMBER have been an essential player in our peripheral nerve product development strategy for a number of years. The new product lines developed are a quantum leap in performance. We have benefitted from the academic team’s experience and ability to “test drive” new approaches outside our normal R&D structure. Site visits by the academic team to our U.S. facilities have been invaluable.”

Dr Simon ArchibaldVice President and Chief ScientistIntegra LifeSciences


Title: Development of “smart” wound care dressings

Engagement type: Consultancy

Industry Partner: Established over 30 years ago and headquartered in Limerick, Fleming Medical is a market leading medical devices company supplying medical equipment, diagnostics, consumables and medicinal products to retail pharmacies, doctors, hospitals, emergency services and primary care throughout Ireland, UK and to other international markets.

Challenge:Fleming Medical were interested in developing a new range of “smart” dressings to allow for more intelligent wound care management.

RCSI value-added A clinical expert who could perform a detailed review of how wound pH, exudate quantity, temperature and pressure impact on the rate of wound healing. Fleming Medical recognised RCSI’s Prof Zena Moore has performed significant research into wound care prevention and treatment in the clinical environment and could offer key opinion leader insight and guidance in delivering a fit-for-purpose product.

FLEMING MEDICAL

“Engaging with RCSI provided us with key opinion leader insight and guidance in delivering a fit-for-purpose product. Our vision for the future is to empower the patient and the physician by providing better patient outcomes for acute and chronic conditions.”

Mark FlemingManaging DirectorFleming Medical


Title: Targeting tumour cells that are resistant to cancer treatment

Engagement Type: Company Fully Funded Project

Industry Partner:Almac Discovery is a research driven oncology business unit within the Almac Group dedicated to the discovery and development of novel, innovative approaches to the treatment of cancer.

Challenge: Cancer stem cells have been shown to be particularly resistant to current treatments and often survive in the tumour niche after surgery and/or chemotherapy. These cells then develop, expand and give rise to a population of tumour cells that can eventually lead to recurrent disease. Almac Discovery is currently focused on discovering new and novel drugs to be used both as single agents, and in combination with new and existing therapies, to treat patients with life-threatening diseases such as cancer.

RCSI Value Add: Expertise in the development of novel approaches for sensitizing cancer stem cells to therapy including the identification and functional characterisation of genes that alter tumour response to anti-cancer agents. In depth knowledge of FKBPL, a protein which occurs naturally in the body and has a unique ability to target therapy resistant cancer stem cells and transform them into more ‘normal’ therapy sensitive tumour cells.

ALMAC

“ALM201 continues to surprise us as we uncover the complexities of its effects. The interaction of ALM201 with cancer stem cells, if proven with this research, opens up potential further treatment options for cancer patients that can be explored in the clinic.”

Stephen Barr President and Managing Director Almac Discovery


Title: Better diagnosis of motor neuron disease

Engagement typeTechnology Licence

Industry partnerAthena Diagnostics, a division of Quest Diagnostics, offers specialty diagnostic testing services for rare neurological disorders through its network of laboratories and patient service centers, and provides interpretive consultation through its extensive medical and scientific staff.

ChallengeAmyotrophic lateral sclerosis (ALS) is one of a group of disorders known as motor neuron diseases. It is characterized by the progressive degeneration and eventual death of nerve cells (motor neurons) in the brain, brainstem and spinal cord that facilitate communication between the nervous system and voluntary muscles of the body. ALS is difficult to diagnose early because it may appear similar to several other neurological diseases.

RCSI value-addResearchers at the Departments of Neurology and Physiology and Medical Physics in RCSI identified and characterised mutations in a gene encoding for Angiogenin (ANG) in ALS patients. Angiogenin is a member of the ribonuclease (RNase) A superfamily and has been described as a hypoxia inducible factor. Previous research in endothelial cells has identified Angiogenin as a potent inducer of neovascularisation, but a role for Angiogenin in neurodegeneration prior to the work of the RCSI research group had not been described. Through their analysis of the angiogenin gene, the RCSI Research Group was able to develop a method of assessing whether an individual is afflicted with, or genetically predisposed to developing, ALS.

“Quest Diagnostics and Athena Diagnostics are the world’s leading providers of diagnostic information services that patients and doctors need to make better healthcare decisions. The ALS assay developed in RCSI aligns well with our company’s vision, namely, Empowering Better Health with Diagnostic Insights.”

Karthik Kuppusamy, Ph.D.General Manager, Neurology SolutionsAthena

ATHENA DIAGNOSTICS


Title: Development of a novel bedding material to prevent pressure ulcers

Engagement Type:Enterprise Ireland Innovation Partnership

Industry Partner:Wellman International is Europe’s largest producer of high quality polyester staple fibres made primarily from post-consumer recycled material for various end-uses.

Challenge: Pressure ulcers, also known as bedsores, are common devastating wounds that extend from deep in the bone and muscle layers through to the skin and commonly occur in older people with limited mobility. They are highly painful, prone to inflection, and in some cases, pressure ulcer complications can result in death. Pressure ulcers are often a trigger for admission into hospital or long stay facilities.

RCSI value-addRCSI’s School of Nursing and Midwifery has performed significant research into wound care prevention and treatment in the clinical environment and contributed to a significant number of Cochrane Systematic reviews. This knowledge helped inform the development of a novel material the company believed could be used in the manufacture of pressure ulcer preventing mattresses.

WELLMAN INTERNATIONAL

“The Innovation Team at RCSI have really facilitated this collaboration. From the very initial meetings focused on identifying project scope and appropriate funding mechanisms all the way through to ensuring efficient conclusion of the collaborative research agreement and valuable advice at monthly project steering group meetings, their support has been outstanding.”

Donal BreenCEOWellman International


Pictured (L-R) are Professor Zena Moore, Head of the RCSI School of Nursing & Midwifery and Celene Dolan, Marketing & Product Manager at Wellman International.


Title: Developing new breast cancer therapies

Engagement type: Enterprise Ireland Innovation Voucher

Industry partner: Inflection Biosciences, based in Dublin and London, is developing small molecule therapeutics for the treatment of cancer. The company’s pipeline of highly innovative cancer treatments comprises IBL-202, IBL-300 selected from a series of unique dual mechanism kinase inhibitors and the IBL-100 series (selective pan-PIM kinase inhibitors), are currently in pre-clinical stages of development. Inflection Biosciences was named ‘Start-up Company of the Year’ at the 2014 Irish Pharma Awards.

Challenge: Inflection Biosciences approached RCSI for assistance in the identification of specific breast cancer patients who may be likely to respond to the company’s therapeutic pipeline.

RCSI value-add: In depth knowledge of current treatment strategies for drug resistant breast cancer and the ability to perform pre-clinical assessment of new compounds targeting that indication.

INFLECTION BIOSCIENCES

“We approached Professor Bryan Hennessy and his team at RCSI due to their understanding of where current breast cancer treatments were failing in the clinic and their passion and capability to assess new cancer therapeutics in treating these resistant patient groups. The results from our initial collaboration have identified breast cancer patients who are more likely to respond to our innovative therapeutic approach.”

Darren CunninghamChief Executive OfficerInflection Biosciences

INFLECTION


Pictured (L-R): Professor Bryan Hennessy, Senior Clinical Lecturer at RCSI, Consultant Medical Oncologist in Beaumont Hospital, Dublin and Our Lady of Lourdes Hospital, Drogheda and Adjunct Professor in the Division of Cancer Medicine at MD Anderson Cancer Centre (MDACC); Darren Cunningham, Chief Executive Officer at Inflection Biosciences, and Dr Michael O’Neill, Director of Research and Development at Inflection Biosciences.


Title:Drug delivery using medical devices

Engagement typeSFI Research Centre Co-Funded Targeted Research Project

Industry partnerAerogen is an innovative medical device and drug delivery company specialising in the design, manufacture and marketing of aerosol drug delivery systems, aimed at the critical care respiratory market.

ChallengeAlthough there are a growing number of small molecule and biomolecule therapeutics under development for respiratory pathologies, translation of these therapies has been hindered by inefficient drug delivery and drug instability. Aerogen’s vibrating mesh nebulisers can deliver large biomolecules to the lungs effectively and the focus of this project is to investigate the delivery of a range of therapeutics in combination with Aerogen’s nebulisers.

RCSI value-addRCSI provided expertise in respiratory medicine, API characterisation, pharmaceutical formulation, pharmacokinetics and controlled release drug delivery systems.

AEROGEN

“Aerogen is an award winning company that continues to invest heavily in R&D and product design. Strategic alliances with leading research institutes such as RCSI have enabled Aerogen to leverage home-grown scientific excellence to facilitate its rapid growth.”

Dr Colin TelferDirector of Business DevelopmentAerogen


RCSI: playing a leading role in national research centres of scale

FutureNeuroFutureNeuro is a RCSI hosted SFI Research Centre focused on addressing the socio-economic burden caused by chronic and rare neurological diseases. In an internationally unique manner, FutureNeuro links innovative neurotherapeutics development with genomic and biomarker-based patient stratification, a national eHealth infrastructure and a nationwide clinical network. The Centre connects national and multinational industry with key academics and clinicians in RCSI, Trinity College Dublin, Dublin City University, NUI Galway and University College Dublin. Building initially on internationally recognised pre-clinical and clinical research into epilepsy and motor neurone disease, the FutureNeuro Centre is a scalable platform that aims to expand quickly to focus on other chronic and rare neurological diseases.

AMBER - Advanced Materials and BioEngineering Research Since its foundation in 2013, the SFI Research Centre AMBER has become an internationally recognised centre of excellence for materials research. The AMBER Centre brings together leading researchers from RCSI’s Tissue Engineering Research Group, the Trinity Centre for Bioengineering (TCBE) and the Trinity Centre for Research on Adaptive Nanostructures and Nanodevices (CRANN) as well as researchers in materials chemistry from UCC and has a strong focus on supporting industry partnerships.

CÚRAM Centre for Research in Medical Devices RCSI is a founding partner in the SFI Research Centre CÚRAM. The CÚRAM centre is focused on improving health outcomes for patients by developing innovative implantable medical devices that can respond to the body’s environment and deliver therapeutic agents, such as drugs, exactly where needed. CÚRAM’s outputs will particularly benefit patients with chronic diseases such as heart disease, diabetes and musculoskeletal diseases.


INFANT RCSI is a founding partner in the SFI Research Centre, INFANT. The INFANT Centre is developing solutions to address the unmet worldwide need for effective screening tests for the most common clinical complications associated with pregnancy and newborn babies.

Irish Centre for Vascular Biology Hosted by RCSI, the Irish Centre for Vascular Biology (ICVB) comprises an integrated network of research groups across Irish hospitals and universities actively engaged in research in the field of vascular biology. The Centre’s mission is to combine and harness the expertise of these individual groups, thereby establishing a single, internationally recognised, national centre of excellence in vascular biology research. In addition to leveraging existing Irish research expertise, the ICVB is building new partnerships with the major stakeholders involved in vascular research, including healthcare providers, patients and industry partners, with the goal of formulating and applying novel, interdisciplinary methods to the study of vascular biology.


IP commercialisation

RCSI has a broad portfolio of patented technologies available for licensing relevant to the medical device, therapeutics, diagnostic, healthcare delivery and medical education sectors. We have

established an experienced, pro-business team in our Office of Research and Innovation to support the licensing of RCSI IP to both established and start-up companies. We welcome interest from companies

who would like to explore licensing and partnering opportunities around our available technologies. For further information on our current portfolio see rcsi.ie/technology_license

Healthcare professional education

Diagnostics Therapeutics Devices Healthcare delivery

Clinical practice


We encourage experienced entrepreneurs and investors to talk to us about the creation of High-Potential Start-up Companies based on RCSI IP or aligned with RCSI’s research focus. Ireland has several government funding schemes to

support entrepreneurs seeking to create High-Potential Start-ups based on IP from higher education institutes including the Enterprise Ireland Business Partner Programme. RCSI’s Office of Research and Innovation can advise entrepreneurs

on accessing these funding schemes and explain how RCSI can support start-up company formation and the technology transfer process. Please contact us if you are interested in investing in or leading early-stage companies.

Start-up company formation

Founders Entrepreneurs Advisors

IP License RCSI Start Up Investors

BUILDING AN RCSI STARTUP COMPANY


RCSI Clinical Research Centre

RCSI Clinical Research Centre, Beaumont Hospital

The RCSI Clinical Research Centre provides state-of-the-art facilities and expertise to enable RCSI investigators conduct clinical research to the highest standards. The Centre is located on the Beaumont Hospital campus, one of RCSI’s principal teaching hospitals in Dublin. Since opening in September 2000, the centre has had more than 24,000 patient visits. During this time, the activities of the Centre have developed a cohort of highly skilled and trained research nurses with the attendant expertise to enable clinical research.

› Consultation rooms - Patient consultations and study visits

› Samples room - Processing of blood and biological samples; storage of biological samples (refrigerator, -20° and -80° freezers).

RCSI Clinical Research Centre facilities include:

› Day ward - Accommodating four patients

› Phlebotomy room - For taking patient blood samples


RCSI’s publications are cited twice as much as the global average (FWCI=1.97). In the period 2012-2017, 1,094 (39.4%) of RCSI’s publications were in the top 10% of journals with 3.6% in the top 1% of journals. (SciVal, CiteScore Data – see graph). Publication and citation numbers for the same period are outlined in the table below.

FWCI = field weighted citation index

ROYAL COLLEGE OF SURGEONS IN IRELAND SCHOLARLY OUTPUT AND CITATIONS

2012 2013 2014 2015 2016 2017

Publications 452 405 425 476 506 651

Total citations of above 9951 7193 8058 7226 3856 959publications to date (Feb 2018)

20070

20

40

60

80

100120

140

160

180

200

220

240 SciVal

2008 2009 2010 2011 2012 2013 2014 2015 2016 2017

Publication Year

Pub

licat

ions

in T

op 1

0 Jo

urna

l Per

cent

iles

Publication impact


Contact Us

Dr Derek John Technology Transfer Case ManagerTel: +353 1 402 2567Email: [email protected]

Dr Aoife GallagherHead of Innovation

Tel: +353 1 402 5132 Email: [email protected]

Michelle Kelly BLResearch Contracts Officer

Tel: +353 1 402 5002Email: [email protected]

Dr Seamus BrowneHead of Industry Partnerships


Cathy O’ByrneAssistant Research Officer



Research featured in the case studies and support provided by RCSI’s ORI is funded by:

Location

THE SWAN PUB

IL POSTO

123

26

121

No. 111


Notes

RCSI Royal College of Surgeons in IrelandColáiste Ríoga na Máinleá in Éirinn123 St Stephen’s Green, Dublin 2Tel: +353 1 402 2100Email: [email protected] Website: rcsi.ie/innovation

rcsi collaborating with industry to improve human … rcsi... · 2018-08-01 · rcsi collaborating...

Documents